Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 12,573 matching trials from the live ClinicalTrials.gov search.
Conditions
Pediatric Feeding Disorder, Chronic, Avoidant Restrictive Food Intake Disorder
Interventions
Cyproheptadine, Nutritional Counseling, Behavioral Counseling
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
2 Years to 6 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Hypoglycemia, Diabetes Mellitus
Interventions
Octreotide (drug)
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee
Conditions
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
Interventions
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more
Conditions
T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting Phase 2 Interventional Results available

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

NCT04624178
Conditions
Leiomyosarcoma
Interventions
Rucaparib, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Lymphoma, Mantle Cell
Interventions
Acalabrutinib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
65 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
32
States / cities
Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
Conditions
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more
Conditions
Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
Interventions
doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
Conditions
NSCLC, Gastric Cancer
Interventions
PEGPH20, Pembrolizumab
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more
Completed Phase 4 Interventional Results available

Fall Epidemic Viral Pediatric Study

NCT01192178
Conditions
Asthma
Interventions
FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
38
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
Conditions
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
Interventions
Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
Radiation · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Not applicable Interventional

The DRAGON 2 Trial

NCT05428735
Conditions
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Interventions
Embolization
Procedure
Lead sponsor
Maastricht University
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Cholangitis, Sclerosing
Interventions
Oral all-trans retinoic acid (ATRA)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Conditions
Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
Interventions
Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
Drug
Lead sponsor
Exelixis
Industry
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Bay Shore, New York • Kettering, Ohio • Memphis, Tennessee + 1 more
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib, Datopotamab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
37
States / cities
Fountain Valley, California • Los Alamitos, California • Los Angeles, California + 32 more
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Gemtuzumab Ozogamicin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Valhalla, New York
Conditions
Solid Tumors
Interventions
Epacadostat, Nivolumab, Ipilimumab, Lirilumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Conditions
Marfan Syndrome
Interventions
Exercise Intervention Group, Control Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Rituximab, Zanubrutinib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery
Drug · Procedure
Lead sponsor
Robert H. Lurie Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Cancer
Interventions
LY2090314, pemetrexed, Carboplatin, ranitidine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Tampa, Florida • Nashville, Tennessee
Conditions
HPV-Negative Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Standard Dose Radiation, Low Dose Radiation, Cisplatin, TFHX Regimen
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
High Blood Pressure
Interventions
Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 59 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California